Tesis Labs and Personal Genome Diagnostics tie-up to advance cancer treatment
The aim is to create new genomics solutions that could combat cancer and advance market access
The aim is to create new genomics solutions that could combat cancer and advance market access
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Advances deployment of mRNA technology across vaccines and therapeutics development
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Price band in the range of Rs 933 to Rs 954
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
With the acquisition of these further shares, TWPL has now become company's subsidiary.
Subscribe To Our Newsletter & Stay Updated